Overview

Phase 4 Study in the Elderly Patients With T2DM

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The study will assess the incidence of Hypoglycemia: Percent of patients presenting no hypoglycemia (confirmed events with SMBG and severe episodes) over 6 months follow up in T2DM patients treated with a DPP-4 inhibitor or another OAD as add-on therapy to metformin

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Vildagliptin